The Digestive Disease Week conference in San Diego unveiled compelling new analysis from a recent Phase 3 clinical trial. The findings suggest that a live biotherapeutic, primarily used to prevent the recurrence of Clostridioides difficile infection, may also enhance mental health parameters, creating a significant correlation with alterations in the gut's microbiome and metabolome. Patients…
A recent study has illuminated the critical role that symbiotic biofilms comprising Bacteroides thetaiotaomicron and C. difficile play in the treatment and prevention of Clostridioides difficile infections (CDI). With the prevalence of CDI in healthcare environments remaining high, this insight into the complex microbial interplay could potentially equip healthcare professionals with improved treatment strategies.
Major public…